Japanese journal of ophthalmology · 2025
Switching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maehara Yusuke, Notomi Shoji, Shiose Satomi, Fukuda Yosuke, Kiyohara Kohei, Kano Kumiko, Ishikawa Keijiro, Hisatomi Toshio, Sonoda Koh-Hei
Аннотация
PURPOSE: To evaluate structural outcomes, including subretinal fluid (SRF) and fibrovascular pigment epithelial detachment (fvPED) volume changes, after switching from aflibercept 2 mg to faricimab in Japanese patients with neovascular age-related macular degeneration (nAMD).
STUDY DESIGN: Retrospective, observational study.
METHODS: Patients with nAMD who were switched from aflibercept 2 mg to faricimab were enrolled. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the volumes of SRF and fvPED were analyzed using three-dimensional spectral-domain optical coherence tomography data.
RESULTS: A total of 46 eyes from 46 patients were included. All had been maintained on fixed dosing due to difficulty in extending the injection interval. Patients had received a mean of 25.6 aflibercept 2 mg injections, with a mean interval of 7.5 weeks for the last three injections. Subsequently, three faricimab injections were given at similar intervals (7.6 weeks). BCVA remained unchanged (p = 0.066), while CMT, SRF, and fvPED volumes significantly decreased (p < 0.01). A significant correlation was found between the reductions in SRF and fvPED volumes (p < 0.05).
CONCLUSIONS: Switching to faricimab led to favorable structural outcomes in nAMD patients previously treated with aflibercept 2 mg, particularly by reducing SRF and fvPED.
STUDY DESIGN: Retrospective, observational study.
METHODS: Patients with nAMD who were switched from aflibercept 2 mg to faricimab were enrolled. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the volumes of SRF and fvPED were analyzed using three-dimensional spectral-domain optical coherence tomography data.
RESULTS: A total of 46 eyes from 46 patients were included. All had been maintained on fixed dosing due to difficulty in extending the injection interval. Patients had received a mean of 25.6 aflibercept 2 mg injections, with a mean interval of 7.5 weeks for the last three injections. Subsequently, three faricimab injections were given at similar intervals (7.6 weeks). BCVA remained unchanged (p = 0.066), while CMT, SRF, and fvPED volumes significantly decreased (p < 0.01). A significant correlation was found between the reductions in SRF and fvPED volumes (p < 0.05).
CONCLUSIONS: Switching to faricimab led to favorable structural outcomes in nAMD patients previously treated with aflibercept 2 mg, particularly by reducing SRF and fvPED.
Предметные рубрики MeSH
HumansRetrospective StudiesFemaleTomography, Optical CoherenceMaleRetinal DetachmentSubretinal FluidReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsIntravitreal InjectionsVisual AcuityWet Macular DegenerationAgedDrug SubstitutionFluorescein AngiographyAged, 80 and overRetinal Pigment EpitheliumFollow-Up StudiesFundus OculiAngiogenesis InhibitorsVascular Endothelial Growth Factor ATreatment OutcomeMiddle AgedDose-Response Relationship, DrugAntibodies, Bispecific